# Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.

> **NCT07335952** · PHASE2 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 179 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** proximod 5mg daily
- **DRUG:** proximod 10mg daily

## Key facts

- **NCT ID:** NCT07335952
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-02
- **Primary completion:** 2025-10-09
- **Final completion:** 2025-10-09
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07335952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07335952, "Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07335952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*